BillionToOne
The genetic testing platform detecting and measuring disease.
Y CombinatorSummer 2017PublicHealthcareDiagnosticsDiagnosticsGenomics
What they do
Problem
Existing prenatal screening and cancer liquid biopsy tests lack sufficient sensitivity and resolution to accurately detect and quantify genetic signals in cell-free DNA from blood.
Solution
A DNA molecular counting platform (commercialized as UNITY Screen and oncology liquid biopsy assays) that boosts cell-free DNA diagnostic resolution to enable highly accurate prenatal and cancer testing from blood samples.
Who it's for
Clinicians and clinical laboratories serving pregnant patients for prenatal screening and oncology providers for liquid biopsy testing.
Founders
Oguzhan Atay
Founder
David Tsao
Founder/CTO
Open roles 6
Company timeline
- Founded2016
- YC batchSummer 2017
- StatusPublic
- Team size300 people
- LocationMenlo Park, CA, USA
Similar startups
Isabl
Cancer tests based on whole genome and transcriptome data.
Natera
Natera is a global leader in DNA testing. It is changing disease mana…
X-Zell
Early, pain-free cancer detection.
Cofactor Genomics
Cofactor closes the precision medicine gap with predictive diagnostics
Coral Genomics
New clinical tests for managing autoimmune treatments.
Kenota (formerly ExVivo Labs)
Kenota is revolutionizing the way we test for disease